<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01394120</url>
  </required_header>
  <id_info>
    <org_study_id>TARGTHPANC 001</org_study_id>
    <secondary_id>2011-001017-13</secondary_id>
    <nct_id>NCT01394120</nct_id>
  </id_info>
  <brief_title>Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer</brief_title>
  <official_title>Phase II Study of Chemotherapy Selection Based on Therapeutic Targets for the Treatment of Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sofia Perea, Director Clinical Trials Unit.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Hospital de Madrid</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In recent years, treatment of advanced pancreatic cancer is changing. Currently, there are&#xD;
      several active schedules of chemotherapy that can be used, such as gemcitabine as monotherapy&#xD;
      or in combination with capecitabine or erlotinib, and FOLFIRINOX. Moreover, the development&#xD;
      of biomarker (therapeutic targets) that can predicte response to treatment is a new important&#xD;
      tool to be used in clinical practice to select the best scheme for each patient. Preliminary&#xD;
      studies showed that therapeutic target determination, using tumor tissue collected from&#xD;
      patients, could determine the presence of groups of &quot;chemotherapy responders&quot;. Such is the&#xD;
      case of EGFR amplification and/or K-Ras gene status and correlation with response to&#xD;
      erlotinib. Moreover, Thymidilate Synthase, Thimidine Phosphorylase, ERCC-1 and Topoisomerase&#xD;
      I expression by immunohistochemistry in GI tumor samples has been related to resistance or&#xD;
      response to 5FU-capecitabine, oxaliplatin and irinotecan respectively. Based on this data the&#xD;
      investigators designed a phase II clinical trial to evaluate the efficacy of selected&#xD;
      treatment for pancreatic cancer patients based on the determination of therapeutic targets.&#xD;
      The therapeutic target-driven treatment efficacy will be compared to the prospective&#xD;
      treatment of a control group of patients treated at the discretion of the&#xD;
      physician-researcher&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Phase: Phase 2 Trial&#xD;
&#xD;
      Study Objetives:&#xD;
&#xD;
        -  Primary end-point. Proportion of patients alive after 12 months in patients with&#xD;
           advanced pancreatic carcinoma individually selected and grouped according to the&#xD;
           expression in tumor tissue for therapeutic targets.&#xD;
&#xD;
        -  Secondary end-points. 1. Assessing the feasibility of the method of&#xD;
           patient-treatment-selection based on tumor tissue expression of therapeutic targets. 2.&#xD;
           Overal survival comparison between Gemcitabine single agent treatment and the rest of&#xD;
           chemotherapy schedules. 3. Determination of progression-free survival for each treatment&#xD;
           group. 4. Determination of toxicity in all the patients.&#xD;
&#xD;
      Study population and Number of subject: A total of 60 pancreatic cancer patients with&#xD;
      advanced pancreas cancer with no previous systemic treatment are expected to be enrolled.&#xD;
&#xD;
      Study design and schedule. Patients will be randomized (1:1) to a control arm or an&#xD;
      experimental treatment arm guided by therapeutic targets. In the control arm, patients are&#xD;
      treated with conventional chemotherapy regimens at the discretion of the investigator. In the&#xD;
      experimental arm, patients are treated as determined in tumor tissue available for biomarker&#xD;
      TS, TP, ERCC-1, Topo-1, K-Ras mutation and EGFR FISH, choosing FOLFIRINOX schemas, FOLFOX,&#xD;
      FOLFIRI, Gemcitabine-Capecitabine Gemcitabine-Erlotinib, Gemcitabine single agent. All&#xD;
      patients will be analyzed by intention to treat&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Carcinoma, Pancreatic Ductal</condition>
  <arm_group>
    <arm_group_label>Tarteted Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Targeted Therapy Tailored Treatment</intervention_name>
    <description>Targeted therapy tailored treatment, based on molecular determination in pancreas cancer specimen&#xD;
Tim Synthase (TS) (neg), ERCC-1 (neg), Topoisomerase I (Topo I) (pos) : FOLFIRINOX&#xD;
TS (neg), ERCC-1 (neg), Topo I (neg): FOLFOX&#xD;
TS (neg), ERCC-1 (pos), Topo I (pos): FOLFIRI&#xD;
TS (neg), ERCC-1 (pos), Topo I (neg): Capecitabine/Gemcitabine&#xD;
TS (pos), EGFR Not Amplificate, K-Ras Mutation (pos) : Gemcitabine single agent&#xD;
TS (pos), EGFR Ampl or K-Ras mut (neg): Gemcitabine plus Erlotinib</description>
    <arm_group_label>Tarteted Therapy</arm_group_label>
    <other_name>Individualized treatment selection based on predictors of response biomarkers</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Chemotherapy</intervention_name>
    <description>Patients treated based on investigatorÂ´s criteria: : FOLFIRINOX, FOLFOX, FOLFIRI, Capecitabine-Gemcitabine, Erlotinib-Gemcitabine or Gemcitabine single agent</description>
    <arm_group_label>Standard Chemotherapy</arm_group_label>
    <other_name>Treatment at the investigator's discretion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic diagnosis of pancreas adenocarcinoma&#xD;
&#xD;
          -  Clinical stage IV&#xD;
&#xD;
          -  Feasible patient for chemotherapy&#xD;
&#xD;
          -  Availability of tumor tissue or possibility of a tumor biopsy to define therapeutic&#xD;
             targets&#xD;
&#xD;
          -  Informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous systemic treatment for advanced pancreas adenocarcinoma&#xD;
&#xD;
          -  Contraindication to the administration of any of the drugs used in the study:&#xD;
             capecitabine, 5Fluouracil, irinotecan, oxaliplatin, gemcitabine or erlotinib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Hidalgo, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Centro Integral Oncologico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Hidalgo, MD, PhD</last_name>
      <email>mhidalgo@cnio.es</email>
    </contact>
    <investigator>
      <last_name>Jesus Rodriguez-Pascual</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Cubillo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pia Morelli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Garcia</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Angulo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulpiano Lopez de la Guardia</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilio de Vicente</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduardo Garcia-Rico</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ignacio Juez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Ruiz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>July 5, 2011</study_first_submitted>
  <study_first_submitted_qc>July 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2011</study_first_posted>
  <last_update_submitted>March 24, 2012</last_update_submitted>
  <last_update_submitted_qc>March 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Grupo Hospital de Madrid</investigator_affiliation>
    <investigator_full_name>Sofia Perea, Director Clinical Trials Unit.</investigator_full_name>
    <investigator_title>Director Clinical Trial Unit</investigator_title>
  </responsible_party>
  <keyword>Pancreas cancer</keyword>
  <keyword>Targeted Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Pancreatic Ductal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

